Pharma 2020: Taxing times ahead - Which path will you take?

The global financial crisis, government pressure, changing market dynamics for an industry experiencing significant change and rapidly evolving healthcare reforms are likely to drive up the effective tax rate for the pharmaceutical and life sciences industry, according to a report by PricewaterhouseCoopers (PwC) entitled Pharma 2020: Taxing times ahead - Which path will you take?. The industry’s response to these trends, including diminishing reliance on the 'blockbuster drug model', will make tax planning more complicated and challenging for tax executives working for pharmaceutical and life sciences companies.

Pharma 2020: Marketing the future

The current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model over the next ten years as the industry shifts from a mass-market to a target-market approach to increase revenue, according to a new report published by PricewaterhouseCoopers (PwC)

Pharma 2020: Virtual R&D – Which path will you take?

Pharma 2020: Virtual R&D – Which path will you take? is the second in a series of papers published by PricewaterhouseCoopers exploring the future of the pharmaceutical industry.